MEDP · Medpace Holdings, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MEDP
this stock
Medpace Holdings, Inc.
|
$16.28B | +4.6% | +20.0% | 34.2 | 6.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$225.93B | +5.2% | +14.5% | 32.9 | 1.5% |
|
DHR
Danaher Corp /De/
|
$140.70B | -12.6% | +8.5% | 35.5 | 1.4% |
|
NTRA
Natera, Inc.
|
$47.01B | +43.6% | -2.8% | — | 3.8% |
|
IQV
Iqvia Holdings Inc.
|
$42.94B | +16.1% | +41.6% | 32.0 | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MEDP | -1.0% | +1.0% | +29.8% | -1.1% | +4.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +0.2% | +2.7% | +12.0% | -0.7% | -7.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.